Citadel Advisors’s Neumora Therapeutics NMRA Stock Holding History

Citadel Advisors’s Portfolio NMRA Stock Details NMRA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$1.41M	Buy	828,933 +485,347	+141%	+$924K	﹤0.01%	7375
2026 Q1	$670K	Sell	343,586 -162,217	-32%	-$420K	﹤0.01%	8591
2025 Q4	$905K	Buy	+505,803	New	+$1.11M	﹤0.01%	7616
2025 Q3	–	Sell	-17,187	Closed	-$27.8K	–	13661
2025 Q2	$12.6K	Buy	+17,187	New	+$13K	﹤0.01%	12179
2025 Q1	–	Sell	-144,769	Closed	-$248K	–	15243
2024 Q4	$1.53M	Buy	144,769 +144,699	+206,713%	+$1.73M	﹤0.01%	6182
2024 Q3	$925	Sell	70 -860,373	-100%	-$10M	﹤0.01%	13933
2024 Q2	$8.46M	Sell	860,443 -963,540	-53%	-$9.97M	﹤0.01%	2995
2024 Q1	$25.1M	Sell	1,823,983 -19,308	-1%	-$312K	﹤0.01%	1846
2023 Q4	$30.3M	Sell	1,843,291 -325,227	-15%	-$3.99M	0.01%	1609
2023 Q3	$29.7M	Buy	+2,168,518	New	+$27.1M	0.01%	1509

Other funds holding NMRA

Siren LLC Greenwich, Connecticut $4.94B AUM 244.43% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

SoftBank Group Tokyo, Japan $18.2B AUM 177.65% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

MCMU

MIC Capital Management (UK) London, United Kingdom $394M AUM 25.64% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Wellcome Trust London, United Kingdom $9.01B AUM 12.05% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Iconiq Capital San Francisco, California $3.47B AUM 23.76% 1-Year Est. Return

Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Citadel Advisors's NMRA Position: Q2 2026 in Review

Citadel Advisors increased its Neumora Therapeutics (NMRA) stake by 141% in Q2 2026, buying an estimated $924K and bringing the position to 828,933 shares worth $1.41M. The position accounts for ﹤0.01% of the portfolio, ranked #7375.

Citadel Advisors first reported a position in NMRA in Q3 2023 and has held it in 10 quarters since. The position peaked at $30.3M in Q4 2023. 113 funds tracked by Wall St. Rank hold NMRA as of Q2 2026.

Citadel Advisors held 828,933 shares of Neumora Therapeutics worth $1.41M as of Q2 2026.
Citadel Advisors bought 485,347 Neumora Therapeutics shares in Q2 2026, an estimated $924K.
Neumora Therapeutics made up ﹤0.01% of Citadel Advisors's portfolio in Q2 2026, its #7375 holding.
Citadel Advisors first reported a position in Neumora Therapeutics in Q3 2023 and has held it in 10 quarters since.
Citadel Advisors's Neumora Therapeutics position peaked at $30.3M in Q4 2023.
113 funds tracked by Wall St. Rank held Neumora Therapeutics as of Q2 2026.

Based on Citadel Advisors's 13F filing for Q2 2026, filed 14 Aug 2026.